ArticleAllergy, asthma & immunology research2017
The Role of IL-17 in a Lipopolysaccharide-Induced Rhinitis Model.
Article in Allergy, asthma & immunology research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Multi-omics insights into dietary zinc-mediated reprogramming of the gut-nasal ecosystem in allergic rhinitis.Frontiers in allergy · 2026Article
- Profile of immune response during nasal challenge with dermatophagoides pteronyssinus in subjects with allergic airway diseases.Journal of inflammation (London, England) · 2024Article
- α-Hemolysin from Staphylococcus aureus Changes the Epigenetic Landscape of Th17 Cells.ImmunoHorizons · 2024Article
- Lidocaine relieves murine allergic rhinitis by regulating the NF-κB and p38 MAPK pathways.Experimental and therapeutic medicine · 2022Article
- Vancomycin-induced gut microbiota dysbiosis aggravates allergic rhinitis in mice by altered short-chain fatty acids.Frontiers in microbiology · 2022Article
- Interleukin-17 Can Be the Target of Novel Treatment Strategies for Particulate Matter-Induced Allergic Diseases.Allergy, asthma & immunology research · 2022Article
- Systemic and local cytokine profile and risk factors for persistent allergic airway inflammation in patients sensitised to house dust mite allergens.BMC pulmonary medicine · 2021Article
- Role of IL-17 in atopy-A systematic review.Clinical and translational allergy · 2021Review
- Effect of lipopolysaccharide and polyinosinic:polycytidylic acid in a murine model of nasal polyp.Scientific reports · 2021Article
- Sneezing and Rubbing Counts in Allergic Rhinitis Mouse Models Are a Reliable Indicator of Type 2 Immune Response.Clinical and experimental otorhinolaryngology · 2020Article
- Analysis the effect of miR-141-3p/HMGB1 in LPS-induced mucus production and the apoptosis in nasal epithelial cells.The Kaohsiung journal of medical sciences · 2020Article
- Inhibition of TLR4 inhibits allergic responses in murine allergic rhinitis by regulating the NF-κB pathway.Experimental and therapeutic medicine · 2019Article
- MicroRNA-17-5p aggravates lipopolysaccharide-induced injury in nasal epithelial cells by targeting Smad7.BMC cell biology · 2018Article
- Effects of Anti-IL-17 on Inflammation, Remodeling, and Oxidative Stress in an Experimental Model of Asthma Exacerbated by LPS.Frontiers in immunology · 2017Article
- MicroRNA-223-3p regulates allergic inflammation by targeting INPP4A.Brazilian journal of otorhinolaryngologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLipopolysaccharide (LPS) is a cell wall component of Gram-negative bacteria and important for pro-inflammatory mediators. This study aimed to establish a rhinitis model using ovalbumin (OVA) and LPS in order to evaluate the role of interleukin (IL)-17 in the pathogenesis of an LPS-induced non-eosionophilic rhinitis model.
methodsMice were divided into 4 groups and each group consisted of 10 mice (negative control group, allergic rhinitis model group, 1-μg LPS treatment group, and 10-μg LPS treatment group). BALB/c mice were sensitized with OVA and 1 or 10 μg of LPS, and challenged intranasally with OVA. Multiple parameters of rhinitis were also evaluated to establish the LPS-induced rhinitis model. IL-17 knockout mice were used to check if the LPS-induced rhinitis model were dependent on IL-17. Eosinophil and neutrophil infiltration, and mRNA and protein expression profiles of cytokine in nasal mucosa or spleen cell culture were evaluated using molecular, biochemical, histopathological, and immunohistological methods.
resultsIn the LPS-induced rhinitis model, neutrophil infiltration increased in the nasal mucosa, and systemic and nasal IL-17 and interferon-gamma (IFN-γ) levels also increased as compared with the OVA-induced allergic rhinitis model. These findings were LPS-dose-dependent. In IL-17 knockout mice, those phenotypes (neutrophil infiltration, IL-17, and IFN-γ) were reversed, showing IL-17 dependency of LPS-induced rhinitis. The expression of vascular endothelial growth factor (VEGF), an important mediator for inflammation and angiogenesis, decreased in IL-17 knockout mice, showing the relationship between IL-17 and VEGF.
conclusionsThis study established an LPS-induced rhinitis model dependent on IL-17, characterized by neutrophil infiltration and increased expression of IL-17.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.